Does prasugrel monotherapy provide a safe and feasible alternative to traditional DAPT in low-risk Japanese patients with CCS undergoing PCI?
Prasugrel monotherapy may be a safe 'aspirin-free' alternative to traditional DAPT following PCI in low-risk patients with chronic coronary syndrome.
This pilot study showed the safety and feasibility of prasugrel monotherapy in selected low-risk Japanese patients with CCS. This "aspirin-free" strategy may be a safe alternative to traditional DAPT following PCI.
Muramatsu et al. (Fri,) studied this question.